Trovagene Investor Relations Trovagene Investor Relations Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075 Activation of first trial site for Phase 1b/2 clinical trial of PCM-075, in combination with standard-of care, to evaluate dose and scheduling, and preliminary anti-leukemic activity Mon, 13 Nov 2017 05:00:00 -0800 Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results Thu, 09 Nov 2017 07:32:00 -0800 Trovagene's PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga® (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells PCM-075 enhances activity of abiraterone in mCRPC tumors cells and may represent a novel treatment option to extend the benefit of anti-androgen therapy Wed, 18 Oct 2017 05:00:00 -0700 FDA Grants Orphan Drug Designation to Trovagene's PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML) Mon, 09 Oct 2017 05:00:00 -0700 Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis Dr. Athena Countouriotis joins Trovagene's Board of Directors, bringing significant experience in oncology clinical development and orphan indications Wed, 20 Sep 2017 05:00:00 -0700